CClinicalTrials.gg
CompletedNCT03263117SEGAUpdated Nov 26, 2025Results posted

SEdation Versus General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke

A Phase 4 interventional study of Sedation and General Anesthesia (GA) in Stroke, sponsored by The University of Texas Health Science Center, Houston. Completed at 11 sites in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2025-11-26.

Sponsored by The University of Texas Health Science Center, Houston · Phase 4, Interventional, and Treatment

Phase
Phase 4
Study type
Interventional
Enrollment
260
Allocation
Randomized
Ages
18 Years to 90 Years
Sex
All
01

Study summary

Objectives:

This study aims to estimate overall treatment benefit (improvement in disability) among acute ischemic stroke patients that are randomized to General Anesthesia (GA) compared with Sedation (CS) during endovascular therapy. Assess safety (as measured by incidence of symptomatic intracranial hemorrhage); rates of Endovascular therapy (EVT) procedural complications, reperfusion; and quality of life.

Hypothesis:

GA during EVT for acute ischemic stroke improves functional outcomes at 90 days compared to sedation.

02

Conditions studied

  • Stroke

Browse trials for

Keywords

  • Acute stroke
  • Cerebral Stroke
03

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  1. Acute ischemic stroke due to large intracranial vessel occlusion demonstrated on CT-angiography in the following anterior circulation locations that will be treated by endovascular therapy (EVT):

    1. Internal Carotid Artery (terminal "T" or "L-type"- occlusion)
    2. Middle Cerebral Artery (MCA) M1 or proximal M2
    3. Anterior Cerebral Artery (ACA) A1 or proximal A2

      • Patients who receive IV-tPA thrombolysis are eligible provided the drug was delivered within 4.5 hours of stroke onset or last seen normal and in accordance with local hospital standard of care.
  2. Ages 18-90.
  3. National Institute of Health Stroke Scale (NIHSS) score 6-30
  4. Time of from stroke symptom onset of last seen normal to start of EVT (defined as groin puncture) ≤ 16 hours.
  5. Limited infarct core, as defined below and adapted from the 2018 American Heart Association guidelines

    1. For patients presenting ≤ 6 hours from time of symptom onset or last seen normal, Alberta Stroke Program Early Computed Tomography Score (ASPECTS) ≥ 6
    2. For patients presenting > 6 hours and ≤ 16 hours from time of symptom onset or last seen normal, they must satisfy EITHER ONE of the two following criteria:

    i. Ischemic core by CT Perfusion or MRI/MR Perfusion \< 70 mL, a ratio of volume of penumbral tissue to infarct core of ≥ 1.8, and and absolute volume of penumbral tissue of ≥ 15 mL OR ii. For patients with NIHSS ≥ 10, infarct core of \< 31 mL by CT Perfusion or MRI; For patients with NIHSS ≥ 20, infarct core \< 51 mL.

  6. Subject willing/able to return for protocol required follow up visits.
  7. No significant pre-stroke disability (modified Rankin Score must be ≤ 2).
  8. Females of childbearing potential must have a negative serum or urine pregnancy test.
  9. Patient or patient's legally authorized representative has given Informed Consent according to Good Clinical Practices (GCP) and/or local IRB policies.

Exclusion criteria

Exclusion Criteria:

  1. Coma on admission (Glasgow Coma Scale \<8), need for intubation upon ED arrival, or transferred patients who present previously intubated.
  2. Severe agitation or seizures on admission that preclude safe vascular access.
  3. Loss of airway protective reflexes and/or vomiting on admission.
  4. Predicted or known difficult airway.
  5. Pre-existing neurological or psychiatric disease that would confound the neurological or functional evaluations, e.g. dementia.
  6. Presumed septic embolus, or suspicion of bacterial endocarditis
  7. Currently participating or has participated in any investigational drug or device study within 30 days.
  8. Inability to follow-up for 90-day assessment.
  9. Known history of allergy to anesthesia drugs.
  10. Known history or family history of malignant hyperthermia
04

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
260 participants (actual)

Study arms

  • Active comparator
    Sedation

    The protocol does not specify a particular combination of drugs that must be used for sedation. The choice of specific drugs and dosages for achieving sedation will be up to the anesthesiologist.

    Drug: Sedation · Procedure: Intra-arterial Thrombectomy

  • Active comparator
    General Anesthesia

    The protocol does not specify a particular combination of drugs that must be used for general anesthesia. The choice of specific drugs and dosages for achieving general anesthesia will be up to the anesthesiologist.

    Drug: General Anesthesia (GA) · Procedure: Intra-arterial Thrombectomy

Interventions

  • DrugSedation

    The protocol does not specify a particular combination of drugs that must be used for sedation. The most common drugs utilized for sedation and wide dosing ranges are included in the protocol (i.e., sedation will be provided under the supervision of an anesthesiologist and may use a combination of fentanyl, midazolam, dexmedetomidine infusion (with or without loading dose), and/or low-dose propofol by intermittent bolus or infusion); however, the choice of specific drugs and dosages for achieving conscious sedation or general anesthesia will not be specified by the protocol but will be up to the anesthesiologist.

  • DrugGeneral Anesthesia (GA)

    The protocol doesn't specify drugs that must be used for GA, the choice of drugs and dosages for achieving general anesthesia will not be specified by the protocol but will be up to the anesthesiologist. The most common drugs utilized for GA and wide dosing ranges included in the protocol are (GA will be provided under the supervision of an anesthesiologist and induction of anesthesia may be achieved with propofol and/or etomidate; muscle paralysis may be achieved with succinylcholine or non-depolarizing paralytic (rocuronium or vecuronium); and adjuvant lidocaine and fentanyl; if intravenous maintenance of anesthesia is used, it may be achieved by propofol infusion at 50 to 150 mcg/kg/min with redosing of non-depolarizing paralytic and fentanyl as needed; if inhalational maintenance of anesthesia is used it will be achieved with sevoflurane 1% to 2% or desflurane 3% to 6% end-tidal concentration with redosing of non-depolarizing paralytic and fentanyl as needed)

  • ProcedureIntra-arterial Thrombectomy

    The first line therapeutic embolectomy device should be a stent retriever. Additional Endovascular therapies including, but not limited to, intra- or extracranial angioplasty ± stenting; antithrombotics (oral, IV or IA antiplatelets or anticoagulants) intra-arterial thrombolytics; are left to the decision of the local treatment team.

    Also known as: Endovascular Therapy

05

What researchers measure

Primary outcomes

  1. Modified Ordinal Rankin Scale (mRS)

    mRS ranges from 0 to 6, with higher scores indicating greater disability. 6 categories are reported: number of participants who had a score of 0, 1, 2, 3, or 4 will be reported separately as 5 categories, and those who had a score of 5 or 6 will be combined and reported as a single category. 0: no symptoms/normal (physical, cognitive etc.) 1. no significant disability despite symptoms; able to carry out all usual duties and activities 2. slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. moderate disability; requiring some help, but able to walk without assistance from another individual (use of walking aids alone is not counted as assistance) 4. moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. dead

    Time frame: 90 days

Secondary outcomes

  1. Dichotomized Modified Ordinal Rankin Scale (mRS)

    The modified Rankin Scale (mRS) ranges from 0 to 6, with higher scores indicating greater disability and where 0-2 is generally considered a good outcome with individuals assuming complete functional independence. 2 categories are reported: number of participants who had a score of 0-2, and number who had a score of 3-6. 0: no symptoms/normal (physical, cognitive etc.) 1. no significant disability despite symptoms; able to carry out all usual duties and activities 2. slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. moderate disability; requiring some help, but able to walk without assistance from another individual (use of walking aids alone is not counted as assistance) 4. moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. dead

    Time frame: 90 days

  2. Number of Participants With Angiographic Reperfusion Defined as Modified a TICI Score of ≥ 2b

    The thrombolysis in cerebral infarction (TICI) grading system is a tool for determining the response of thrombolytic therapy for ischemic stroke. The TICI grade ranges from 0 to 3, with a higher score indicating greater perfusion. grade 0: no perfusion grade 1: penetration with minimal perfusion grade 2: partial perfusion grade 2A: only partial filling (less than two-thirds) of the entire vascular territory is visualized grade 2B: complete filling of all of the expected vascular territory is visualized but the filling is slower than normal grade 3: complete perfusion

    Time frame: post procedure within 6 hours

  3. Score on the National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS)

    The National Institutes of Health Stroke Scale (NIHSS) is a tool used objectively quantify the impairment caused by a stroke. Total score ranges from 0 - 42, with a higher score indicating greater severity of impairment caused by stroke. 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke

    Time frame: 24-36 hours post procedure

  4. Number of Participants With Functional Independence as Indicated by an mRS Score of 0, 1, or 2

    The modified Rankin Scale (mRS) ranges from 0 to 6, with higher scores indicating greater disability and where 0-2 is generally considered a good outcome with individuals assuming complete functional independence. 0: no symptoms/normal (physical, cognitive etc.) 1. no significant disability despite symptoms; able to carry out all usual duties and activities 2. slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. moderate disability; requiring some help, but able to walk without assistance from another individual (use of walking aids alone is not counted as assistance) 4. moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. dead

    Time frame: 90 days

  5. Quality of Life as Assessed by the European Quality of Life (EuroQol) 5 Dimensions 5 Level Version (EQ-5D-5L) Assessment

    The EQ-5D-5L score ranges from -0.59 to 1, where 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0.

    Time frame: 90 days

  6. Number of Participants With Symptomatic Intracerebral Hemorrhage

    Symptomatic intracerebral hemorrhage was defined using the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition, a ≥ 4 point increase in NIHSS score with a parenchymal hemorrhage type 2 within 36 hours.

    Time frame: 18-36 hours post procedure

  7. Number of Participants With All-cause Mortality

    Time frame: 18-36 hours post procedure

  8. Number of Participants With Procedural Complications

    Time frame: 18-36 hours post procedure

Other outcomes

  1. Time From Groin Puncture to Reperfusion

    Time frame: post procedure within 6 hours

  2. Time From Door to TICI ≥ 2b Reperfusion

    Time frame: post procedure within 6 hours

06

Results

Posted Sep 5, 2024

Participant flow

Participant flow — Overall Study
MilestoneSedationGeneral Anesthesia
Started130130
Pass screening129128
Completed120120
Not completed1010

Outcome measures

PrimaryModified Ordinal Rankin Scale (mRS)

mRS ranges from 0 to 6, with higher scores indicating greater disability. 6 categories are reported: number of participants who had a score of 0, 1, 2, 3, or 4 will be reported separately as 5 categories, and those who had a score of 5 or 6 will be combined and reported as a single category. 0: no symptoms/normal (physical, cognitive etc.) 1. no significant disability despite symptoms; able to carry out all usual duties and activities 2. slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. moderate disability; requiring some help, but able to walk without assistance from another individual (use of walking aids alone is not counted as assistance) 4. moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. dead

Time frame:
90 days
Reported as:
Count of participants · Participants
Modified Ordinal Rankin Scale (mRS)
ParticipantsGeneral AnesthesiaSedation
score of 01611
score of 12123
score of 22013
score of 32124
score of 4916
score of 5 or 63333
SecondaryDichotomized Modified Ordinal Rankin Scale (mRS)

The modified Rankin Scale (mRS) ranges from 0 to 6, with higher scores indicating greater disability and where 0-2 is generally considered a good outcome with individuals assuming complete functional independence. 2 categories are reported: number of participants who had a score of 0-2, and number who had a score of 3-6. 0: no symptoms/normal (physical, cognitive etc.) 1. no significant disability despite symptoms; able to carry out all usual duties and activities 2. slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. moderate disability; requiring some help, but able to walk without assistance from another individual (use of walking aids alone is not counted as assistance) 4. moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. dead

Time frame:
90 days
Reported as:
Count of participants · Participants
Dichotomized Modified Ordinal Rankin Scale (mRS)
ParticipantsGeneral AnesthesiaSedation
Score of 0, 1, or 25747
Score of 3, 4, 5, or 66373
SecondaryNumber of Participants With Angiographic Reperfusion Defined as Modified a TICI Score of ≥ 2b

The thrombolysis in cerebral infarction (TICI) grading system is a tool for determining the response of thrombolytic therapy for ischemic stroke. The TICI grade ranges from 0 to 3, with a higher score indicating greater perfusion. grade 0: no perfusion grade 1: penetration with minimal perfusion grade 2: partial perfusion grade 2A: only partial filling (less than two-thirds) of the entire vascular territory is visualized grade 2B: complete filling of all of the expected vascular territory is visualized but the filling is slower than normal grade 3: complete perfusion

Time frame:
post procedure within 6 hours
Reported as:
Count of participants · Participants
Number of Participants With Angiographic Reperfusion Defined as Modified a TICI Score of ≥ 2b
ParticipantsGeneral AnesthesiaSedation
Number of Participants With Angiographic Reperfusion Defined as Modified a TICI Score of ≥ 2b118116
SecondaryScore on the National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS)

The National Institutes of Health Stroke Scale (NIHSS) is a tool used objectively quantify the impairment caused by a stroke. Total score ranges from 0 - 42, with a higher score indicating greater severity of impairment caused by stroke. 0 No stroke symptoms 1-4 Minor stroke 5-15 Moderate stroke 16-20 Moderate to severe stroke 21-42 Severe stroke

Time frame:
24-36 hours post procedure
Reported as:
Median · score on a scale
Score on the National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS)
score on a scaleGeneral AnesthesiaSedation
Score on the National Institutes of Health Stroke Scale, or NIH Stroke Scale (NIHSS)7 (3 to 14)6 (3 to 14)
SecondaryNumber of Participants With Functional Independence as Indicated by an mRS Score of 0, 1, or 2

The modified Rankin Scale (mRS) ranges from 0 to 6, with higher scores indicating greater disability and where 0-2 is generally considered a good outcome with individuals assuming complete functional independence. 0: no symptoms/normal (physical, cognitive etc.) 1. no significant disability despite symptoms; able to carry out all usual duties and activities 2. slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance 3. moderate disability; requiring some help, but able to walk without assistance from another individual (use of walking aids alone is not counted as assistance) 4. moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance 5. severe disability; bedridden, incontinent and requiring constant nursing care and attention 6. dead

Time frame:
90 days
Reported as:
Count of participants · Participants
Number of Participants With Functional Independence as Indicated by an mRS Score of 0, 1, or 2
ParticipantsGeneral AnesthesiaSedation
Number of Participants With Functional Independence as Indicated by an mRS Score of 0, 1, or 25747
SecondaryQuality of Life as Assessed by the European Quality of Life (EuroQol) 5 Dimensions 5 Level Version (EQ-5D-5L) Assessment

The EQ-5D-5L score ranges from -0.59 to 1, where 1 is the best possible health state. Negative values represent health states perceived as worse than dead, which is equal to 0.

Time frame:
90 days
Reported as:
Mean · score on a scale
Quality of Life as Assessed by the European Quality of Life (EuroQol) 5 Dimensions 5 Level Version (EQ-5D-5L) Assessment
score on a scaleGeneral AnesthesiaSedation
Quality of Life as Assessed by the European Quality of Life (EuroQol) 5 Dimensions 5 Level Version (EQ-5D-5L) Assessment0.47 ± 0.440.46 ± 0.40
SecondaryNumber of Participants With Symptomatic Intracerebral Hemorrhage

Symptomatic intracerebral hemorrhage was defined using the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST) definition, a ≥ 4 point increase in NIHSS score with a parenchymal hemorrhage type 2 within 36 hours.

Time frame:
18-36 hours post procedure
Reported as:
Count of participants · Participants
Number of Participants With Symptomatic Intracerebral Hemorrhage
ParticipantsGeneral AnesthesiaSedation
Number of Participants With Symptomatic Intracerebral Hemorrhage13
SecondaryNumber of Participants With All-cause Mortality
Time frame:
18-36 hours post procedure
Reported as:
Count of participants · Participants
Number of Participants With All-cause Mortality
ParticipantsGeneral AnesthesiaSedation
Number of Participants With All-cause Mortality119
SecondaryNumber of Participants With Procedural Complications
Time frame:
18-36 hours post procedure
Reported as:
Count of participants · Participants
Number of Participants With Procedural Complications
ParticipantsGeneral AnesthesiaSedation
Number of Participants With Procedural Complications45
Other pre-specifiedTime From Groin Puncture to Reperfusion
Time frame:
post procedure within 6 hours
Reported as:
Median · minutes
Time From Groin Puncture to Reperfusion
minutesGeneral AnesthesiaSedation
Time From Groin Puncture to Reperfusion41 (25 to 66)43 (29 to 65)
Other pre-specifiedTime From Door to TICI ≥ 2b Reperfusion
Time frame:
post procedure within 6 hours
Reported as:
Median · minutes
Time From Door to TICI ≥ 2b Reperfusion
minutesGeneral AnesthesiaSedation
Time From Door to TICI ≥ 2b Reperfusion121 (90 to 149)116 (93 to 138)

Adverse events

Collected over from baseline to 90 days after discharge. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
General Anesthesia11/130 (8.5%)62/130 (47.7%)0/130 (0%)
Sedation9/130 (6.9%)65/130 (50%)0/130 (0%)
Most frequent serious events
Most frequent serious events
EventGeneral AnesthesiaSedation
intracerebral hemorrhage asymptomaticVascular disorders59/13059/130
Procedure ComplicationsSurgical and medical procedures4/1305/130
intracerebral hemorrhage symptomaticVascular disorders1/1303/130

Baseline characteristics

Baseline characteristics were only collected for participants who were randomized and pass screening.

Age, Continuous
Age, Continuous(years)General AnesthesiaSedationTotal
Mean65.9 ± 12.767.6 ± 13.866.77 ± 13.28
Sex: Female, Male
Sex: Female, Male(Participants)General AnesthesiaSedationTotal
Female6955124
Male5974133
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)General AnesthesiaSedationTotal
Hispanic or Latino232144
Not Hispanic or Latino98100198
Unknown or Not Reported7815
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)General AnesthesiaSedationTotal
Race — White6465129
Race — Black383775
Race — Asian325
Race — More than one race7714
Race — Unknown161834
Region of Enrollment
Region of Enrollment(participants)General AnesthesiaSedationTotal
United States128129257
Number of Participants who received intravenous tissue-type plasminogen activator treatment
Number of Participants who received intravenous tissue-type plasminogen activator treatment(Participants)General AnesthesiaSedationTotal
Count of participants7872150
Number of Participants with Atrial Flutter/Atrial Fibrillation
Number of Participants with Atrial Flutter/Atrial Fibrillation(Participants)General AnesthesiaSedationTotal
Count of participants233255
Number of Participants with a history of diabetes
Number of Participants with a history of diabetes(Participants)General AnesthesiaSedationTotal
Count of participants263460

14 further baseline measures are reported on the registry.

07

Study locations

11 sites
  • Indiana University College of Medicine
    Indianapolis, Indiana 46202, United States
  • University of Iowa Hospitals and Clinics
    Iowa City, Iowa 52242, United States
  • Henry Ford Health System
    Louisville, Kentucky 48150, United States
  • Rochester Regional Health
    Rochester, New York 14617, United States
  • Wake Forest Baptist Health
    Winston-Salem, North Carolina 27157, United States
  • Geisinger Health
    Danville, Pennsylvania 17822, United States
  • Temple University
    Philadelphia, Pennsylvania 19122, United States
  • Memorial Hermann Hospital System - Memorial City Medical Center
    Houston, Texas 77024, United States
  • Baylor College of Medicine
    Houston, Texas 77030, United States
  • University of Texas Health Science Center Houston with Memorial Hermann Hospital System - The Medical Center
    Houston, Texas 77030, United States
  • Memorial Hermann Hospital System - The Woodlands Medical Center
    The Woodlands, Texas 77380, United States
08

References and documents

Publications

  • Chen PR, Artime CA, Sheth SA, Pedroza C, Ortega-Gutierrez S, Wolfe S, Sitton C, Kan P, Tanweer O, Chebl A, Schirmer CM, Morrow JT, Alderazi YJ, Bohnstedt B, Erkmen K, Samaniego EA, Garrido E, Savitz SI, Engstrom A, Aguilar E, Nguyen T, Barreto AD; SEGA Investigators. Sedation vs General Anesthesia for Endovascular Therapy in Acute Ischemic Stroke: The SEGA Randomized Clinical Trial. JAMA Neurol. 2025 Dec 1;82(12):1265-1273. doi: 10.1001/jamaneurol.2025.3775. PubMed 41082222 ↗
  • Tosello R, Riera R, Tosello G, Clezar CN, Amorim JE, Vasconcelos V, Joao BB, Flumignan RL. Type of anaesthesia for acute ischaemic stroke endovascular treatment. Cochrane Database Syst Rev. 2022 Jul 20;7(7):CD013690. doi: 10.1002/14651858.CD013690.pub2. PubMed 35857365 ↗

Study documents

  • Protocol and statistical analysis plan · May 10, 2022

Documents are hosted by the registry — open the source record to download them.

09

Registry details

Key details

Study ID
NCT03263117
Lead sponsor
The University of Texas Health Science Center, Houston
Collaborators
Stryker Neurovascular
Responsible party
Peng Roc Chen, MD (Professor in Neurosurgery, The University of Texas Health Science Center, Houston) — Principal investigator
First posted
Aug 28, 2017
Start date
Jul 1, 2018
Primary completion
Apr 22, 2023
Completion
Apr 22, 2023
Results posted
Sep 5, 2024
Last update
Nov 26, 2025

Study contacts

Peng Roc Chen, MD
study chair · The University of Texas Health Science Center, Houston
Andrew Barreto, MD
principal investigator · The University of Texas Health Science Center, Houston
Carlos Artime, MD
principal investigator · The University of Texas Health Science Center, Houston
Sunil Sheth, MD
principal investigator · The University of Texas Health Science Center, Houston
Sean Savitz, MD
principal investigator · The University of Texas Health Science Center, Houston
Claudia Pedroza, PhD
principal investigator · The University of Texas Health Science Center, Houston

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Sep 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion